Contact
searchSearch
HMP Global
Login

News

News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
News
Pembrolizumab Plus Weekly Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer
10/17/2025
Janelle Bradley
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial reveal that pembrolizumab combined with weekly paclitaxel, with or without bevacizumab, significantly prolonged PFS and OS vs chemotherapy alone in patients with platinum-resistant...
Results from the phase 3...
10/17/2025
Oncology
FDA Approval
FDA Accepts New Drug Application for Relacorilant as a Treatment for Patients With Platinum-Resistant Ovarian Cancer
09/10/2025
Allison Casey
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for relacorilant as a treatment for patients with platinum-resistant ovarian cancer.
The FDA has accepted an NDA for...
09/10/2025
Oncology
News
Alpelisib Plus Olaparib Fails to Improve Outcomes For Platinum-Resistant/Platinum-Refractory High-Grade Serous Ovarian Cancer
08/19/2025
Stephanie Holland
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis results from the phase 3 EPIK-O/ENGOT-ov61 trial, alpelisib plus olaparib did not improve outcomes among previously treated patients with platinum-resistant or platinum-refractory high-grade serous ovarian cancer...
According to primary analysis...
08/19/2025
Oncology
FDA Approval
FDA Approves Avutometinib Plus Defactinib for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
05/08/2025
Stephanie Holland
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the RAMP-201 trial, the FDA has approved avutometinib plus defactinib for previously treated patients with KRAS-mutated recurrent low-grade serous ovarian cancer.
Based on results from the...
05/08/2025
Oncology
News
TTFields Plus Paclitaxel Fails to Improve Survival Among Pretreated Patients With Platinum-Resistant Ovarian Cancer
04/29/2025
Stephanie Holland
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial, tumor treating fields plus paclitaxel did not improve survival compared to paclitaxel alone among pretreated patients with platinum-resistant ovarian cancer.
According to results from the...
04/29/2025
Oncology
News
Relacorilant Plus Nab-Paclitaxel Improves PFS for Patients With Platinum-Resistant Ovarian Cancer
04/04/2025
Stephanie Holland
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel improved survival among patients with platinum-resistant ovarian cancer.
Results from the phase 3 ROSELLA...
04/04/2025
Oncology
Toon Van Gorp, MD, PhD, University Hospital Leuven
Videos
Mirvetuximab Soravtansine Confirmed Standard of Care for Folate Receptor Alpha-Positive, Platinum-Resistant Ovarian Cancer
03/17/2025
Toon Van Gorp, MD, PhD
Dr Van Gorp shares insights on the final analysis of the MIRASOL trial evaluating mirvetuximab soravtansine among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.
Dr Van Gorp shares insights on the final analysis of the MIRASOL trial evaluating mirvetuximab soravtansine among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer.
Dr Van Gorp shares insights on...
03/17/2025
Oncology
Conference Coverage
Datopotamab Deruxtecan Shows Promise for Unresectable Advanced Endometrial and Ovarian Cancers
09/12/2024
Allison Casey
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the TROPION-2 study, datopotamab deruxtecan monotherapy demonstrated encouraging efficacy and safety among patients with recurrent endometrial or ovarian cancer.
According to results of the...
09/12/2024
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use